This trial is evaluating whether Quality-of-Life Assessment will improve 6 primary outcomes and 13 secondary outcomes in patients with Recurrent Glioblastoma. Measurement will happen over the course of Up to 28 days.
This trial requires 60 total participants across 3 different treatment groups
This trial involves 3 different treatments. Quality-of-Life Assessment is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"While some patients with glioblastomas may have long-term survival as a result of therapy, others live only a few months following diagnosis. Further studies are required to identify the variables predictive of prognosis in glioblastoma, and to assess the possible role of radiation and chemotherapy in this aggressive tumour." - Anonymous Online Contributor
"GBM is a fatal brain cancer that can form as well as a tumor that can be benign in appearance. In many cases, patients survive for a while after initial diagnosis, even when they have a high grade, invasively growing tumor. GBM often begins with a non-malignant tumor whose grade increases with time from onset to diagnosis. Patients often have trouble adjusting to life with the disease because of the loss of health, mobility and ability to work. The average length of survival for the disease is only about 12–18 months." - Anonymous Online Contributor
"Recent findings underscore the limitations of clinical signs for diagnostic detection of glioblastomas in routine clinical practice. Brain MRI is a safe examination and the presence of T2-weighted hyperintense lesions without enhancement on contrast material should prompt further investigation of these lesions, which may represent brain tumours including glioblastomas." - Anonymous Online Contributor
"Although glioblastoma is the most common [brain tumor](https://www.withpower.com/clinical-trials/brain-tumor) and has been associated with unusually short survival compared with other brain tumors, data are scarce on trends in overall survival for this tumor. Results from a recent clinical trial suggests that mortality rates from this tumor are unlikely to be decreasing among the population, but trends in overall survival should be monitored." - Anonymous Online Contributor
"Pro- and anti-tumor effects of many of the investigated agents in GBM were not statistically significant. Although some compounds are used in glioma therapy, no potent and safe agents can be identified to treat this disease. Clinical use of most GBM-specific agents, such as temozolomide and vincristine, can be only limited. Further work in identification of potentially effective treatment for GBM is required." - Anonymous Online Contributor
"Genetic heterogeneity in glioblastomas has recently received significant attention using genomic technologies and high throughput methods. In the past this heterogeneity was considered an impediment to developing effective personalized medicine and was considered indicative of treatment resistance. Findings from a recent study obtained in the present study point out a different image as a potential benefit: a very heterogeneous tumor where an individualizing personalized therapy based on the profiling of individual patients is possible. However, this approach would imply a more complete knowledge of GBM biology, the definition of molecular subtype, and an individualized therapy." - Anonymous Online Contributor
"In this post hoc analysis, there was greater benefit in the overall improvement in quality-of-life scores when the QOL questionnaire was compared to a placebo, as opposed to a control. Further prospective trials, using QOL as an outcome measure are required to fully demonstrate the efficacy of QOL-focused therapies. Randomized, controlled trials were funded by the National Brain Tumour Foundation of Canada (NBTFC-NCOG). Clinically funded trials of the same interventions have also been undertaken by clinicians in Ontario and Western Australia. These trials, funded by the NBTFC are currently underway and are aiming to confirm the utility of QOL as a primary outcome." - Anonymous Online Contributor
"In a recent study, findings demonstrated that the survival rates of glioblastoma improved significantly when the patients had a complete resection of the glioblastoma and had a younger age. It seems the survival rates could be improved further by the adjuvant therapy." - Anonymous Online Contributor
"The authors' results suggest that while the patient with glioblastoma may be a suitable person for clinical trials, they would also be candidates for trials for patients with limited dissemination." - Anonymous Online Contributor
"Concerns are raised about the implications of QoL assessment for people with glial tumors. This work could be useful in informing oncologists when selecting patients for QoL assessment and in developing patient information to assist in the decision making process." - Anonymous Online Contributor
"Results from a recent clinical trial indicate that the use of the SF-36 and the EORTC QLQ-C30 provides information about a patient's quality of life that is complementary to that provided by a traditional health-related quality-of-life scale such as the HADS and EORTC QLQ-C30 scales. Thus these instruments are preferable to traditional health-related quality-of-life scales for patient and patient-caregiver assessment." - Anonymous Online Contributor
"QoL is determined with the EQ-5D-5L in glioblastoma patients, and it is influenced by treatment choice and tumor location. In a recent study, findings of the present study have implications for patient counseling." - Anonymous Online Contributor